The global market for Pulmonary Edema Therapeutics was valued at US$2.2 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 1.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Pharmacological treatments for pulmonary edema primarily include diuretics, such as furosemide, which help to reduce fluid accumulation by promoting its excretion through the kidneys. Vasodilators like nitroglycerin are also used to decrease the pressure in the blood vessels, reducing the workload on the heart and helping to alleviate fluid buildup in the lungs. In cases where pulmonary edema is caused by heart failure, medications like ACE inhibitors or beta-blockers may be prescribed to improve heart function. Non-pharmacological treatments can include oxygen therapy to improve oxygen levels in the blood and mechanical ventilation in severe cases to support breathing. Additionally, lifestyle modifications, such as reducing salt intake and managing fluid balance, are essential components of long-term management for patients with chronic conditions that predispose them to pulmonary edema.
The growth in the pulmonary edema therapeutics market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases, which are a major cause of pulmonary edema, has significantly boosted the demand for effective treatments. Secondly, advancements in medical research have led to the development of new and improved pharmacological therapies that offer better efficacy and safety profiles. The aging global population, which is more prone to heart-related conditions and respiratory issues, has further fueled market growth. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets has increased the availability of pulmonary edema treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery and commercialization of innovative therapies. Lastly, heightened awareness and early diagnosis of pulmonary edema among healthcare professionals and patients have driven the demand for timely and effective therapeutic interventions, solidifying the market's growth trajectory.
Global Pulmonary Edema Therapeutics Market - Key Drivers and Trends Summarized
Pulmonary edema is a serious medical condition characterized by the accumulation of fluid in the lungs' air sacs, leading to impaired gas exchange and difficulty breathing. This condition can result from various causes, including congestive heart failure, acute respiratory distress syndrome (ARDS), high altitude, and exposure to certain toxins or medications. The primary goal of pulmonary edema treatment is to remove the excess fluid, improve oxygenation, and address the underlying cause. Therapeutic approaches typically involve a combination of pharmacological and non-pharmacological interventions, tailored to the patient's specific condition and severity.Pharmacological treatments for pulmonary edema primarily include diuretics, such as furosemide, which help to reduce fluid accumulation by promoting its excretion through the kidneys. Vasodilators like nitroglycerin are also used to decrease the pressure in the blood vessels, reducing the workload on the heart and helping to alleviate fluid buildup in the lungs. In cases where pulmonary edema is caused by heart failure, medications like ACE inhibitors or beta-blockers may be prescribed to improve heart function. Non-pharmacological treatments can include oxygen therapy to improve oxygen levels in the blood and mechanical ventilation in severe cases to support breathing. Additionally, lifestyle modifications, such as reducing salt intake and managing fluid balance, are essential components of long-term management for patients with chronic conditions that predispose them to pulmonary edema.
The growth in the pulmonary edema therapeutics market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases, which are a major cause of pulmonary edema, has significantly boosted the demand for effective treatments. Secondly, advancements in medical research have led to the development of new and improved pharmacological therapies that offer better efficacy and safety profiles. The aging global population, which is more prone to heart-related conditions and respiratory issues, has further fueled market growth. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets has increased the availability of pulmonary edema treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery and commercialization of innovative therapies. Lastly, heightened awareness and early diagnosis of pulmonary edema among healthcare professionals and patients have driven the demand for timely and effective therapeutic interventions, solidifying the market's growth trajectory.
Report Scope
The report analyzes the Pulmonary Edema Therapeutics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Type (Cardiogenic Pulmonary Edema, Non-Cardiogenic Pulmonary Edema); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Cardiogenic Pulmonary Edema Therapeutics segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of a 1.8%. The Non-Cardiogenic Pulmonary Edema Therapeutics segment is also set to grow at 1.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $593.4 Million in 2024, and China, forecasted to grow at an impressive 3.6% CAGR to reach $463 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Bayer AG, Citius Pharmaceuticals, Inc., Edesa Biotech, Exponential Biotherapies, Genentech, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Pulmonary Edema Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pulmonary Edema Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Pulmonary Edema Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 48 major companies featured in this Pulmonary Edema Therapeutics market report include:
- Bayer AG
- Citius Pharmaceuticals, Inc.
- Edesa Biotech
- Exponential Biotherapies
- Genentech, Inc.
- Lupin Ltd.
- Pantherna Therapeutics GmbH
- Pfizer Inc.
- Qx Therapeutics, Inc.
- Sun Pharmaceutical Industries Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Citius Pharmaceuticals, Inc.
- Edesa Biotech
- Exponential Biotherapies
- Genentech, Inc.
- Lupin Ltd.
- Pantherna Therapeutics GmbH
- Pfizer Inc.
- Qx Therapeutics, Inc.
- Sun Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 285 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.2 Billion |
| Forecasted Market Value ( USD | $ 2.4 Billion |
| Compound Annual Growth Rate | 1.6% |
| Regions Covered | Global |
